

Quality by Design— An Indispensable Approach to Accelerate Biopharmaceutical Product Development

M. Amin Khan
Cristiana Campa
Editors



www.pda.org/bookstore

This page intentionally left blank

Quality by Design— An Indispensable Approach to Accelerate Biopharmaceutical Product Development

M. Amin Khan
Cristiana Campa
Editors

To order the book, please visit: go.pda.org/QbD



Parenteral Drug Association, Inc. – *Connecting People, Science and Regulation*, Bethesda, MD
20815

© 2021 Parenteral Drug Association, Inc.

All rights reserved. 2021

23 22 21 20 19 18 17 16

1 2 3 4 5

ISBN: 978-1-945584-22-0



TABLE OF CONTENTS

Preface	v
Foreward	vi
PART I : INTRODUCTION	1
Introduction	2
Quality by Design Principles	3
A Case Study	8
PART II : PRODUCT UNDERSTANDING	15
Section 1: Critical Quality Attributes and Ranges	16
1. Critical Quality Attribute Determination and Establishing Acceptable Ranges for Monoclonal Antibodies	18
2. Critical Quality Attribute Assessment and Definition of Acceptable Limits for IgG1 Monoclonal Antibodies	33
3. Critical Quality Attributes Acceptance Criteria and Patient-Centric Quality Standards	50
4. Biopharmaceutical Analytical Acceleration Strategies: Platforms, Critical Quality Attributes, and Specifications	60
5. Critical Quality Attributes and Ranges for a Glycoconjugate-Based Vaccine in Development: A Case Study	72
Section 2: Formulation Development	91
6. Identification of Critical Quality Attributes in Adjuvanted Vaccines: An Essential Step for Enabling Acceleration and Cost-Effective Formulation Development	93
7. Formulation and Product Development of a mAb1: A Case Study in Acceleration at Various Stages of Product Development	112
Section 3: Stability Modeling	131
8. Using Prior Knowledge for Stability Modeling of Biological Therapeutic Agents to Assign Shelf Life	133
9. Stability Modeling in Quality by Design: Accelerating Formulation Development and Predicting Shelf Life of Vaccine Products	169
10. Stability Modeling for Biopharmaceutical Process Intermediates	200

Section 4: Comparability	226
11. Comparability Assessment for Vaccines Development and Lifecycle	228
<hr/>	
PART III: PROCESS UNDERSTANDING AND MODELING	238
Section 5: Process Understanding and Modeling	239
12. Using Quality-by-Design Principles to Increase Process Understanding for a mAb Drug Substance Manufacturing Process	241
13. Approach to Speeding Up Process Understanding Without Compromising on Quality: A Vaccine Case Study	268
14. Accelerating Product and Process Development Through a Model-Centric Approach	285
<hr/>	
PART IV: ANALYTICAL STRATEGY AND MODELING	339
Section 6: Analytical Strategy and Modeling	340
15. Leveraging Quality-by-Design Principles to Accelerate Analytical Strategy: A Case Study for Glycoconjugate-Based Vaccines	342
16. Quality by Design—A Versatile Concept for Targeted Method Development	363
17. Accelerating Attribute-Focused Analytical Development	396
18. Predictive Modeling in the Analytical Space	412
<hr/>	
PART V: PLATFORM KNOWLEDGE	420
Section 7: Platform Knowledge	421
19. Platform Knowledge to Accelerate Adenovirus-Based Vaccine Development	423
20. mRNA Vaccines: A Disruptive Platform Technology To Accelerate Development	460
21. Platform Raw Material Risk Assessment for a Monoclonal Antibody Drug Substance Process	482
<hr/>	
PART VI: CONCLUSIONS	496
Conclusions	497
Index	501